Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking Post published:July 16, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated Workshop Discusses Ketamine; EMA Associates Publish Recap of Psychedelics Workshop Post published:July 12, 2024 Post category:Psychedelic Bulletin/Pα+
Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD Post published:July 9, 2024 Post category:Analysis/News/Pα+
Natural Medicine Advisory Bulletin 12: May and June 2024 Post published:July 8, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo Post published:July 5, 2024 Post category:Psychedelic Bulletin/Pα+
Funding the Future of Psychedelic Medicine in Europe: An Interview with Norrsken Mind Post published:July 3, 2024 Post category:Interviews
Pα+ Psychedelic Bulletin #165: A Closer Look at a Buzzy Oral Ketamine for Depression Study; UN Weighs In on Psychedelics; Another CA Psychedelics Bill Fails Post published:June 28, 2024 Post category:Psychedelic Bulletin/Pα+
In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds Post published:June 27, 2024 Post category:Analysis/News
No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD Post published:June 21, 2024 Post category:Analysis/News/Pα+
Natural Medicine Advisory Bulletin 11.6: June 14th Subcommittee: Problems with Products Post published:June 21, 2024 Post category:Colorado Natural Medicine Advisory Bulletin